173 related articles for article (PubMed ID: 27235717)
1. The ibrutinib B-cell proliferation inhibition is potentiated in vitro by dexamethasone: Application to chronic lymphocytic leukemia.
Manzoni D; Catallo R; Chebel A; Baseggio L; Michallet AS; Roualdes O; Magaud JP; Salles G; Ffrench M
Leuk Res; 2016 Aug; 47():1-7. PubMed ID: 27235717
[TBL] [Abstract][Full Text] [Related]
2. Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia.
Voltan R; Rimondi E; Melloni E; Rigolin GM; Casciano F; Arcidiacono MV; Celeghini C; Cuneo A; Zauli G; Secchiero P
Oncotarget; 2016 Oct; 7(43):70623-70638. PubMed ID: 27661115
[TBL] [Abstract][Full Text] [Related]
3. Antihistamines are synergistic with Bruton's tyrosine kinase inhibiter ibrutinib mediated by lysosome disruption in chronic lymphocytic leukemia (CLL) cells.
Chanas-Larue A; Villalpando-Rodriguez GE; Henson ES; Johnston JB; Gibson SB
Leuk Res; 2020 Sep; 96():106423. PubMed ID: 32712432
[TBL] [Abstract][Full Text] [Related]
4. Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib.
Guo A; Lu P; Galanina N; Nabhan C; Smith SM; Coleman M; Wang YL
Oncotarget; 2016 Jan; 7(4):4598-610. PubMed ID: 26717038
[TBL] [Abstract][Full Text] [Related]
5. CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia.
Montraveta A; Lee-Vergés E; Roldán J; Jiménez L; Cabezas S; Clot G; Pinyol M; Xargay-Torrent S; Rosich L; Arimany-Nardí C; Aymerich M; Villamor N; López-Guillermo A; Pérez-Galán P; Roué G; Pastor-Anglada M; Campo E; López-Guerra M; Colomer D
Oncotarget; 2016 Feb; 7(5):5507-20. PubMed ID: 26701728
[TBL] [Abstract][Full Text] [Related]
6. Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia.
Del Papa B; Baldoni S; Dorillo E; De Falco F; Rompietti C; Cecchini D; Cantelmi MG; Sorcini D; Nogarotto M; Adamo FM; Mezzasoma F; Silva Barcelos EC; Albi E; Iacucci Ostini R; Di Tommaso A; Marra A; Montanaro G; Martelli MP; Falzetti F; Di Ianni M; Rosati E; Sportoletti P
Clin Cancer Res; 2019 Dec; 25(24):7540-7553. PubMed ID: 31578228
[TBL] [Abstract][Full Text] [Related]
7. Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study.
Niemann CU; Herman SE; Maric I; Gomez-Rodriguez J; Biancotto A; Chang BY; Martyr S; Stetler-Stevenson M; Yuan CM; Calvo KR; Braylan RC; Valdez J; Lee YS; Wong DH; Jones J; Sun C; Marti GE; Farooqui MZ; Wiestner A
Clin Cancer Res; 2016 Apr; 22(7):1572-82. PubMed ID: 26660519
[TBL] [Abstract][Full Text] [Related]
8. Changes in T-cell subpopulations and cytokine network during early period of ibrutinib therapy in chronic lymphocytic leukemia patients: the significant decrease in T regulatory cells number.
Podhorecka M; Goracy A; Szymczyk A; Kowal M; Ibanez B; Jankowska-Lecka O; Macheta A; Nowaczynska A; Drab-Urbanek E; Chocholska S; Jawniak D; Hus M
Oncotarget; 2017 May; 8(21):34661-34669. PubMed ID: 28416773
[TBL] [Abstract][Full Text] [Related]
9. TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib.
Dadashian EL; McAuley EM; Liu D; Shaffer AL; Young RM; Iyer JR; Kruhlak MJ; Staudt LM; Wiestner A; Herman SEM
Cancer Res; 2019 Jan; 79(2):360-371. PubMed ID: 30498085
[TBL] [Abstract][Full Text] [Related]
10. Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia.
Maharaj K; Powers JJ; Achille A; Deng S; Fonseca R; Pabon-Saldana M; Quayle SN; Jones SS; Villagra A; Sotomayor EM; Sahakian E; Pinilla-Ibarz J
Blood Adv; 2018 Nov; 2(21):3012-3024. PubMed ID: 30425065
[TBL] [Abstract][Full Text] [Related]
11. Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia.
Hing ZA; Mantel R; Beckwith KA; Guinn D; Williams E; Smith LL; Williams K; Johnson AJ; Lehman AM; Byrd JC; Woyach JA; Lapalombella R
Blood; 2015 May; 125(20):3128-32. PubMed ID: 25838351
[TBL] [Abstract][Full Text] [Related]
12. The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia.
Xargay-Torrent S; López-Guerra M; Rosich L; Montraveta A; Roldán J; Rodríguez V; Villamor N; Aymerich M; Lagisetti C; Webb TR; López-Otín C; Campo E; Colomer D
Oncotarget; 2015 Sep; 6(26):22734-49. PubMed ID: 26068951
[TBL] [Abstract][Full Text] [Related]
13. Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib.
Yu J; Chen L; Cui B; Wu C; Choi MY; Chen Y; Zhang L; Rassenti LZ; Widhopf Ii GF; Kipps TJ
Leukemia; 2017 Jun; 31(6):1333-1339. PubMed ID: 27904138
[TBL] [Abstract][Full Text] [Related]
14. Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies.
Gayko U; Fung M; Clow F; Sun S; Faust E; Price S; James D; Doyle M; Bari S; Zhuang SH
Ann N Y Acad Sci; 2015 Nov; 1358():82-94. PubMed ID: 26348626
[TBL] [Abstract][Full Text] [Related]
15. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.
Till KJ; Pettitt AR; Slupsky JR
J Immunol; 2015 Mar; 194(5):2439-46. PubMed ID: 25632006
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.
Cervantes-Gomez F; Lamothe B; Woyach JA; Wierda WG; Keating MJ; Balakrishnan K; Gandhi V
Clin Cancer Res; 2015 Aug; 21(16):3705-15. PubMed ID: 25829398
[TBL] [Abstract][Full Text] [Related]
17. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
Fraietta JA; Beckwith KA; Patel PR; Ruella M; Zheng Z; Barrett DM; Lacey SF; Melenhorst JJ; McGettigan SE; Cook DR; Zhang C; Xu J; Do P; Hulitt J; Kudchodkar SB; Cogdill AP; Gill S; Porter DL; Woyach JA; Long M; Johnson AJ; Maddocks K; Muthusamy N; Levine BL; June CH; Byrd JC; Maus MV
Blood; 2016 Mar; 127(9):1117-27. PubMed ID: 26813675
[TBL] [Abstract][Full Text] [Related]
18. Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy.
de Rooij MF; Kuil A; Kater AP; Kersten MJ; Pals ST; Spaargaren M
Blood; 2015 Apr; 125(14):2306-9. PubMed ID: 25838279
[No Abstract] [Full Text] [Related]
19. Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia.
Rozovski U; Harris DM; Li P; Liu Z; Jain P; Ferrajoli A; Burger J; Thompson P; Jain N; Wierda W; Keating MJ; Estrov Z
Leuk Lymphoma; 2018 Nov; 59(11):2686-2691. PubMed ID: 29465264
[TBL] [Abstract][Full Text] [Related]
20. Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.
Da Roit F; Engelberts PJ; Taylor RP; Breij EC; Gritti G; Rambaldi A; Introna M; Parren PW; Beurskens FJ; Golay J
Haematologica; 2015 Jan; 100(1):77-86. PubMed ID: 25344523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
